Bellicum pharmaceuticals, inc. (BLCM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenues
Revenues

0

5,133

103

1,391

516

312

292

362

154

-

126

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Grants

-

-

-

-

-

-

-

-

-

-

-

-

128

81

114

101

92

34

57

84

107

14

660

554

552

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

128

81

114

101

92

34

57

84

107

14

660

554

552

Operating expenses
Research and development

10,448

13,497

14,331

19,859

16,848

20,227

16,413

18,412

16,536

14,308

18,101

17,959

15,295

15,084

13,290

12,031

10,858

10,039

9,792

8,012

5,718

4,190

2,257

3,235

2,389

License fees

-

-

0

173

-

-

139

150

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License fees

-

-

-

-

-

-

-

-

-

-

-

-

355

300

0

150

130

-

-

-

-

-

-

-

-

General and administrative

4,171

5,709

9,209

7,518

7,536

6,971

6,968

5,367

5,692

5,053

4,579

5,486

5,927

4,210

4,252

4,179

4,284

3,816

3,882

2,777

2,197

2,003

1,300

592

440

Total operating expenses

14,619

19,033

23,540

27,550

24,384

26,879

23,520

23,929

22,258

19,376

22,831

23,788

21,577

19,594

17,542

16,360

15,272

17,039

13,674

10,789

7,915

49,405

3,557

3,827

2,829

Loss from operations

-14,619

-13,900

-23,437

-26,159

-23,868

-26,567

-23,228

-23,567

-22,104

-19,445

-22,705

-23,788

-21,449

-19,513

-17,428

-16,259

-15,180

-17,005

-13,617

-10,705

-7,808

-49,391

-2,897

-3,273

-2,277

Other income (expense):
Other income (expense):
Interest income

354

307

323

311

410

443

492

437

267

267

284

307

197

222

224

236

227

209

211

171

50

20

9

3

3

Interest expense

985

1,043

1,079

1,088

1,070

1,086

1,065

1,045

1,003

965

1,010

976

721

637

515

486

122

12

0

0

0

1,753

11

11

16

Change in fair value of warrant and private placement option liabilities

-32,826

-

4,850

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,197

-

-

Other expense

-

-

2,989

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

-

-

-

-

-

-

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Total other income (expense)

32,195

-15,081

-8,595

-777

-660

-653

-573

-608

-736

-2,473

-726

-669

-524

-425

-291

-250

105

157

209

171

50

-24,907

-1,199

-8

-13

Net income (loss)

17,576

-28,981

-32,032

-26,936

-24,528

-27,220

-23,801

-24,175

-22,840

-21,918

-23,431

-24,457

-21,973

-19,938

-17,719

-16,509

-15,075

-16,848

-13,408

-10,534

-7,758

-74,298

-4,096

-3,281

-2,290

Less: undistributed earnings to participating securities

12,084

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

328

564

540

Net income (loss) attributable to common shareholders

5,492

-

-

-

-24,528

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-74,298

-4,424

-3,845

-2,830

Net income (loss) per common share attributable to common shareholders, basic (in shares)

1.09

-

-

-

-5.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share attributable to common shareholders, diluted (in shares)

1.09

-

-

-

-5.54

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, basic (in shares)

5,039

-

-

-

4,424

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, diluted (in shares)

5,040

-

-

-

4,424

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings Per Share, Basic and Diluted

-

-

-0.68

-0.58

-

-22.54

-0.55

-0.60

-0.68

-0.64

-0.71

-0.74

-0.80

-0.74

-0.66

-0.61

-0.56

-0.63

-0.51

-0.40

-0.30

-28.63

-2.08

-1.81

-1.52

Weighted-average shares outstanding-basic and diluted (in shares)

-

-

47,208

46,052

-

-101,304

43,334

40,605

33,456

33,307

33,178

33,074

27,295

27,044

26,966

26,910

26,882

26,481

26,376

26,268

26,259

3,928

2,124

2,119

1,863

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities, net of tax

0

-

-8

5

51

-

33

36

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain (loss) on investment securities

-

-

-

-

-

-

-

-

-58

-

22

-16

-7

-61

-18

152

246

-98

0

-204

0

-

0

0

-

Net Income (Loss) Attributable to Parent

17,576

-28,981

-32,032

-26,936

-24,528

-27,220

-23,801

-24,175

-22,840

-21,918

-23,431

-24,457

-21,973

-19,938

-17,719

-16,509

-15,075

-16,848

-13,408

-10,534

-7,758

-74,298

-4,096

-3,281

-2,290

Other comprehensive loss:
Foreign currency translation adjustment

-13

-187

-23

-46

28

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,738

-7,758

-

-4,096

-3,281

-

Comprehensive income (loss)

17,563

-

-32,063

-26,977

-24,449

-

-23,768

-24,139

-22,898

-

-23,409

-24,473

-21,980

-

-17,737

-16,357

-14,829

-

-13,408

-

-

-

-

-

-